Infraredx Announces 15 Scientific Presentations on TVC Imaging System at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) Conference

TCT 2014

BURLINGTON, Mass.--()--Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery disease, announced today that its first-in-class, dual-modality intravascular imaging technology, the TVC Imaging System™, will be highlighted in live cases and over 15 presentations during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2014), the world's largest educational meeting specializing in interventional cardiovascular medicine. TCT 2014 will be held Sept.13-17 at the Walter E. Washington Convention Center in Washington D.C.

The TVC Imaging System utilizes a combination of near-infrared spectroscopy (NIRS) to detect lipid-core plaques (LCPs) and enhanced intravascular ultrasound (IVUS) to visualize plaque structure. LCP is a fatty coronary artery plaque that complicates stenting and is associated with most heart attacks. The TVC Imaging System can identify plaques suspected to be vulnerable to rupture, and those ruptures can cause a fatal coronary blockage.

At TCT 2014, Infraredx will debut a new, experiential learning booth, located at 1313, designed to showcase the utility of NIRS-IVUS imaging with the TVC Imaging System, which clinicians can use to detect the location of plaque and calculate the lipid core burden index of the imaged artery. The booth also will feature a demonstration of the Phillips/TVC Imaging System integration.

Following is a schedule of talks and presentations featuring the TVC Imaging System:

 

Saturday, Sept. 13

1 p.m.
Level 1, Room 103A

CANARY: Evaluation of The Relationship Between Intravascular Ultrasound and Near Infrared Spectroscopy Lipid Parameters with Peri-Procedural Myonecrosis, with An Integrated Randomized Trial of Distal Protection to Prevent PCI Related Myocardial Infarction

Gregg W. Stone
 
2:12 p.m.
Level 1, Room 150A/B

NIRS Utility in the Unstable Patient with ACS/NSTEMI

David Erlinge
 
2:36 p.m.
Level 1, Room 150A/B

NIRS for Identifying Vulnerable Plaque Prior to Coronary Thrombosis

Akiko Maehara
 
3:15 p.m.
Level 1, Room 150A/B

NIRS for Preventing Periprocedural Complications of PCI

Emmanouil S.Brilakis
 
3:43 p.m.
Level 1, Room 150A/B

Avoiding Long-term Complications with PCI: Imaging Guidance with NIRS

James A. Goldstein
 
4:10 p.m.
Level 1, Room 150A/B

TCT 398: Identification of Vulnerable Patients by Intracoronary Near-Infrared Spectroscopy

Ryan D. Madder
 

------------------------

Sunday, Sept. 14

 
6:30 a.m. Breakfast
7-8 a.m. Industry-Sponsored CME Symposia
Level 1, Room 143B

Integrating Physiology and Imaging Into the Cath Lab: What Technology Should I Use, and How and When Should I Use It?

[NOTE: To attend, please register at http://www.crf.org/tct.]

 
11:09 a.m.
Level 2, Room 204B

Imaging Guidance in Difficult Anatomy: IVUS, OCT, and NIR

Akiko Maehara
 
12 p.m.
Level 1, Room 146B/C

Intravascular Imaging: IVUS, OCT, and NIRS

Stephen P. Hoole
 
1:24 p.m.
Level 1, Room 144B

Invasive Imaging for Vulnerable Plaque: Comparing and Contrasting VH-IVUS, OCT, and NIRS

Akiko Maehara
 
1:40 p.m.
Level 1, Room 144B

Focal Treatment of Vulnerable Plaque: Stents, Scaffolds, and Prospect II

Gregg W. Stone
 
5:00 p.m.
Level 1, Room 151A/B

Update on Neoatherosclerosis: Frequency, Diagnosis, and Treatment

Soo-Jin Kang
 
5:12 p.m.
Level 1, Room 150A/B

Physiology Studies Evaluating Clinical Outcomes Using iFR: FLAIR, SweedeHeart, Syntax II, and Prospect II

Javier Escaned
 

---------------------------

Monday, Sept. 15

 
12:00 p.m.
Room: Level 1, Room 146B/C

Intravascular Imaging: IVUS, OCT, and NIRS

Stephen P. Hoole
 
2 p.m.
Level 1, Room 150A/B

IVUS Assessment of ACS and Vulnerable Plaque: Review of PROSPECT, VIVA, and ATHEREMO-IVUS and New Data on the Interpretation of Greyscale Plaque Morphology

Soo-Jin Kang
 
2:25 p.m.
Level 1, Room 150A/B

Predicting Periprocedural MI by Intravascular Imaging (Grayscale-IVUS, VH-IVUS, IB-IVUS, iMAP, and NIRS-IVUS)

Patrick A. Calvert
 

----------------------------

Tuesday, Sept. 16

 
11:00 a.m.
Lower Level, Coronary Theater
Live Case from Thoraxcenter, ERASMUS Medical Center, Rotterdam, The Netherlands
 

About The TVC Imaging System™

The TVC Imaging System™ is a first-in-class intravascular imaging system that is designed to change the way coronary artery disease is managed by providing information that is critical for evaluating vessel structure and composition, also known as true vessel characterization. The TVC Imaging System helps interventional cardiologists identify which patients are prone to complications during stenting. The device enables cardiologists to predict the risk of peri-procedural heart attacks by assessing not only the degree of stenosis, but also the presence and extent of LCPs.

The device is the only commercially available multimodality imaging system to combine both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). Through IVUS technology, the TVC Imaging System provides clear and relevant information about vessel structure, in real time. The TVC Imaging System is the only device specifically approved in both the U.S. and Europe for the detection of LCPs. NIRS measurements have been made in over 10,000 patients in over 100 hospitals worldwide.

About Infraredx, Inc.

Infraredx, Inc. is a privately funded medical device company dedicated to providing practitioners with information needed for enhanced clinical decision-making in treating coronary artery disease. The Company is committed to improving the safety and efficacy of coronary stenting and expects to ultimately serve as part of a strategy to provide secondary and eventually primary prevention of coronary events.

The Company’s TVC Imaging System™ is designed to change the way coronary artery disease is diagnosed and treated. The TVC Imaging System is the only intravascular imaging system that enables true vessel characterization through simultaneous structural and compositional imaging data obtained in a single pullback. Founded in 1998, Infraredx is headquartered in Burlington, Mass. For more information, visit www.infraredx.com.

Contacts

Infraredx, Inc.
Grant Frazier, 781-345-9632
Vice President of Marketing
gfrazier@infraredx.com
or
Pure Communications, Inc.
Media:
Susan Heins, 864-286-9597
sjheins@purecommunicationsinc.com

Release Summary

Infraredx Announces 15 Scientific Presentations on TVC Imaging System at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) Conference

Contacts

Infraredx, Inc.
Grant Frazier, 781-345-9632
Vice President of Marketing
gfrazier@infraredx.com
or
Pure Communications, Inc.
Media:
Susan Heins, 864-286-9597
sjheins@purecommunicationsinc.com